What's breaking now, across thousands of outlets.
MILAN — As more GLP-1-based drugs reach late-stage trials and post stronger and stronger weight loss effects, companies that want to enter the market are looking for differentiating factors. Regeneron has hit on something new and ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
Mayo Clinic researchers report encouraging early results from an experimental therapy targeting the genetic cause of a rare form of amyotrophic lateral sclerosis, or ALS.
→ Juan Andres will come out of retirement to rejoin Moderna as COO on Oct. 5, bringing his intimate knowledge of the company as its Merck-partnered cancer vaccine gathers momentum in the clinic.
Abu Dhabi- Seha, subsidiary of PureHealth, an integrated healthcare platform in the Middle East, has successfully managed a rare and potentially life-threatening neurological case at Sheikh Tahnoon…
Western biopharma companies are increasingly turning to China to source innovation, as pharma's dreaded "patent cliff" draws closer.
Western biopharma companies are increasingly turning to China to source innovation, as pharma's dreaded "patent cliff" draws closer.
As our lives become increasingly digital, vision care will need to evolve alongside them.
